ACADIA Pharmaceuticals Croissance future
Future contrôle des critères 5/6
ACADIA Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 41.3% et de 10.2% par an respectivement. Le BPA devrait croître de de 40% par an. Le rendement des capitaux propres devrait être 30.8% dans 3 ans.
Informations clés
41.3%
Taux de croissance des bénéfices
40.0%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.3% |
| Taux de croissance des recettes | 10.2% |
| Rendement futur des capitaux propres | 30.8% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 22 Oct 2024 |
Mises à jour récentes de la croissance future
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Recent updates
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 1,172 | 264 | 290 | 444 | 16 |
| 12/31/2025 | 1,053 | 150 | 143 | 224 | 19 |
| 12/31/2024 | 952 | 85 | 138 | 260 | 20 |
| 6/30/2024 | 891 | 31 | 80 | 81 | N/A |
| 3/31/2024 | 814 | -2 | 24 | 64 | N/A |
| 12/31/2023 | 726 | -61 | -23 | 17 | N/A |
| 9/30/2023 | 632 | -149 | -133 | -93 | N/A |
| 6/30/2023 | 551 | -111 | -74 | -34 | N/A |
| 3/31/2023 | 520 | -146 | -56 | -56 | N/A |
| 12/31/2022 | 517 | -216 | -114 | -114 | N/A |
| 9/30/2022 | 512 | -217 | -113 | -113 | N/A |
| 6/30/2022 | 512 | -205 | -130 | -130 | N/A |
| 3/31/2022 | 493 | -214 | -142 | -142 | N/A |
| 12/31/2021 | 484 | -168 | -127 | -126 | N/A |
| 9/30/2021 | 474 | -192 | -133 | -130 | N/A |
| 6/30/2021 | 463 | -262 | -141 | -136 | N/A |
| 3/31/2021 | 458 | -260 | -155 | -147 | N/A |
| 12/31/2020 | 442 | -282 | -144 | -136 | N/A |
| 9/30/2020 | 419 | -268 | -144 | -138 | N/A |
| 6/30/2020 | 393 | -225 | -139 | -134 | N/A |
| 3/31/2020 | 366 | -238 | -137 | -136 | N/A |
| 12/31/2019 | 339 | -235 | -152 | -151 | N/A |
| 9/30/2019 | 300 | -248 | -162 | -161 | N/A |
| 6/30/2019 | 264 | -268 | -186 | -184 | N/A |
| 3/31/2019 | 238 | -276 | -189 | -186 | N/A |
| 12/31/2018 | 224 | -245 | -170 | -167 | N/A |
| 9/30/2018 | 208 | -249 | -160 | -158 | N/A |
| 6/30/2018 | 185 | -252 | -175 | -174 | N/A |
| 3/31/2018 | 158 | -256 | N/A | -192 | N/A |
| 12/31/2017 | 125 | -289 | N/A | -218 | N/A |
| 9/30/2017 | 93 | -299 | N/A | -251 | N/A |
| 6/30/2017 | 63 | -306 | N/A | -242 | N/A |
| 3/31/2017 | 33 | -309 | N/A | -240 | N/A |
| 12/31/2016 | 17 | -271 | N/A | -208 | N/A |
| 9/30/2016 | 5 | -238 | N/A | -182 | N/A |
| 6/30/2016 | 0 | -206 | N/A | -165 | N/A |
| 3/31/2016 | 0 | -174 | N/A | -138 | N/A |
| 12/31/2015 | 0 | -164 | N/A | -122 | N/A |
| 9/30/2015 | 0 | -147 | N/A | -105 | N/A |
| 6/30/2015 | 0 | -133 | N/A | -91 | N/A |
| 3/31/2015 | 0 | -115 | N/A | -78 | N/A |
| 12/31/2014 | 0 | -92 | N/A | -66 | N/A |
| 9/30/2014 | 0 | -76 | N/A | -59 | N/A |
| 6/30/2014 | 0 | -62 | N/A | -51 | N/A |
| 3/31/2014 | 1 | -50 | N/A | -39 | N/A |
| 12/31/2013 | 1 | -38 | N/A | -32 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ACAD ( 41.3% par an) est supérieure au taux d'épargne ( 2.5% ).
Bénéfices vs marché: Les bénéfices de ACAD ( 41.3% par an) devraient croître plus rapidement que le marché US ( 15.2% par an).
Croissance élevée des bénéfices: Les bénéfices de ACAD devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ACAD ( 10.2% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ACAD ( 10.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ACAD devrait être élevé dans 3 ans ( 30.8 %)